← Leaderboards
Christopher Horvath
Intica Biomedical, Inc.
$408,507
Attributed
$617,014
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $467.2K · FY2012–13$500K$375K$250K$125K$0
'12
'13
Funding mix
By agency
NIH$617,014 · 2
By mechanism
R41$417,014 · 1
N43$200,000 · 1
Top collaborators
- Sunil S. Badve2 shared
Most similar at Intica Biomedical, Inc.
Same institution · by research overlap
- Sunil S. Badve$2,522,361
Others in their field
Top investigators on “Triple-Negative Invasive Breast Carcinoma”
- Zaver M Bhujwalla · Johns Hopkins University$11,565,510
- Anna Karolina Palucka · Jackson Laboratory$11,495,404
- Fergus Joseph Couch · Mayo Clinic Rochester$11,114,811
- Charles M Perou · Univ Of North Carolina Chapel Hill$9,173,876
- Steven E Artandi · Stanford University$8,619,281
- Jamboor K Vishwanatha · University Of North Texas Hlth Sci Ctr$7,736,848
Research focus
Triple-Negative Invasive Breast CarcinomaPathway InteractionsMalignant NeoplasmsResearch And DevelopmentXenograft ModelCompanionsDiagnosticIn VivoPancreatic AdenocarcinomaPrimary NeoplasmTumorVascular Endothelial CellContractsCancer Stem CellAngiogenesisCell LineGlioblastomaIn VitroNeoplasm MetastasisNeoplastic CellCancer PatientAnoikisCancer DiagnosticsCancer Cell Line
Grant awards (3)
Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St$149,799
R41 · FY2013 · CA · contact PI
Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St$267,215
R41 · FY2012 · CA · contact PI
R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)$200,000
N43 · FY2012 · CA · contact PI